BiotechTube
Home/Spexis/Juergen Froehlich, M.D.
JF

Juergen Froehlich, M.D.

Chief Medical Officer

Spexis

Therapeutic Areas

Rare DiseasesOncologyInfectious Diseases

Spexis Pipeline

DrugIndicationPhase
ColiFin®Cystic FibrosisMarketed (EU)
Inhaled MurepavadinCystic Fibrosis (Pseudomonas aeruginosa infection)Phase 1
OMPTA LPS & BamA ProgramMultidrug-Resistant Gram-negative InfectionsPre-clinical
OMPTA LptA Thanatin ProgramMultidrug-Resistant Gram-negative InfectionsPre-clinical

Leadership Team at Spexis

JD
Jeffrey D. Wager, M.D.
Chief Executive Officer
View full Spexis profile